Product details
Catalog number BNC882976-100
Price for BNC882976-100
Size / count 1x 100 µL
The Ret proto-oncogene is structurally related to the growing family of tyrosine kinase transmembrane receptors and is involved in GDNF signaling. RET expression is reported in several regions of the central nervous system; in the developing cranial nerve ganglia and a subset of cells within dorsal root ganglia, in motor neurons in the spinal cord and hindbrain, in neuro-retina and the growing tips of the renal collecting ducts in developing kidney. Alterations in RETgene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma, and a congenital developmental disorder known as Hirschsprung's disease. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.
The catalog number for RET Proto-oncogene (RET/2976), CF488A conjugate, 0.1mg/mL is BNC882976-100.
RET Proto-oncogene (RET/2976), CF488A conjugate, 0.1mg/mL is available in the following size(s): 1x 100 µL.
RET Proto-oncogene (RET/2976), CF488A conjugate, 0.1mg/mL is currently made to order / not held in immediate stock. Contact us for lead time.
RET Proto-oncogene (RET/2976), CF488A conjugate, 0.1mg/mL is manufactured by Biotium.
Estimated delivery time for RET Proto-oncogene (RET/2976), CF488A conjugate, 0.1mg/mL is approximately 15 business day(s), depending on your location.
The safety data sheet for RET Proto-oncogene (RET/2976), CF488A conjugate, 0.1mg/mL is available here: https://cdn.gentaur.com/products/37/68dd02a2061270361e1048fe/msds/bnc882976-100.pdf.
The Ret proto-oncogene is structurally related to the growing family of tyrosine kinase transmembrane receptors and is involved in GDNF signaling. RET expression is reported in several regions of the central nervous system; in the developing cranial nerve ganglia and a subset of cells within dorsal
Suitability for Co-IP depends on the specific antibody and is noted under validated applications on the datasheet. If it isn’t listed, contact our technical support team for guidance based on your target and sample type.
Automation compatibility varies by kit and isn’t always listed on the datasheet. Contact our technical support team with details of your platform so we can confirm with the manufacturer.
Validated applications such as WB, ELISA, IHC, ICC, or FC are listed on the product datasheet. If you need application-specific validation data before ordering, contact our technical support team with the catalogue number.